<DOC>
	<DOCNO>NCT00722150</DOCNO>
	<brief_summary>The purpose study determine impact vary dos artesunate treatment outcome whether high dos artesunate overcome problem compromise artemisinin sensitivity region . To determine safety tolerability previously untested experimental high dose ( 6 mg/Kg/D X 7 day , total 42 mg/Kg ) artesunate monotherapy regimen .</brief_summary>
	<brief_title>Artemisinin Resistance Cambodia II</brief_title>
	<detailed_description>A total 150 volunteer acute uncomplicated falciparum malaria randomly assign one 3 arm treat artesunate monotherapy 7 day ratio 2:1:2 . Arm 2 serf control serve bridge ARC 1 study perform 2006/2007 . Patients Arm 1 receive relatively low `` standard '' dose , patient Arm 2 receive intermediate dose 4 mg/kg use ARC1 study . Patients Arm 3 receive experimental `` high-dose '' regimen . Currently available safety data extend subject receive 28 mg/Kg total dose 7 day another study administer 8 mg/Kg/day 3 day ( total dose 24 mg/Kg ) . Subjects randomize study 's 'high-dose ' Arm 3 , therefore , receive total dose high previously study human . The study design base WHO recommendations 'Assessment Monitoring Antimalarial Drug Efficacy Treatment Uncomplicated Falciparum Malaria ' ( WHO , 2003 ) .</detailed_description>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemisinine</mesh_term>
	<criteria>1 . Acute symptomatic falciparum malaria infection determine malaria smear parasite density 1000 200,000 asexual parasites/Microliter determine thick/thin screen smear fever ( define ≥ 37.5ºC ) , report history fever within last 48 hour . 2 . Age : 1865 year old 3 . All female age 18 50 require negative human chorionic gonadotropin ( hCG ) pregnancy test ( urine ) . All female childbearing potential ( surgically sterile , less two year menopausal ) require use acceptable method contraception , implant , injectable , oral contraceptive ( ) , possible additional barrier contraception , intrauterine device , sexual abstinence , vasectomized partner , throughout study . 4 . Written inform consent obtain 5 . Willing stay close medical supervision study duration 42 day 6 . Otherwise healthy Outpatients 1 . Pregnant woman , nurse mother , woman childbearing potential use acceptable method contraception ( describe Inclusion Criteria , # 3 ) 2 . Mixed malaria infection admission malaria smear 3 . A previous history intolerance hypersensitivity study drug artesunate drug similar chemical structure , artemether , artemisinin dihydroartemisinin 4 . History malaria drug therapy administer past 30 day 5 . Previous participation trial , participation study involve investigational market product , concomitantly within 30 day prior entry study 6 . History significant cardiovascular , liver renal functional abnormality clinically significant illness , opinion investigator would place increase risk . 7 . Symptoms severe vomit ( food inability take food previous 8 hour ) . 8 . Signs symptom severe malaria ( adapt WHO recommendation ( 2003 ) : prostration , impaired consciousness , respiratory distress , convulsion , systolic blood pressure &lt; 70 mm Hg , abnormal bleeding , severe anemia hemoglobin &lt; 8 g/dL HCT &lt; 24 % , hyperparasitemia &gt; 4 % parasitized red blood cell ) . 9 . Unable and/or unlikely comprehend and/or follow protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Artesunate</keyword>
	<keyword>Plasmodium Falciparum</keyword>
	<keyword>Cambodia</keyword>
</DOC>